IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	Nalan Utku and Steven Richard Blumberg
U.S. Serial No.	:	Not Yet Known (national stage of PCT International Application No. PCT/EP2004/014435)
Filed	:	Herewith
For	:	USE OF AGENTS DERIVED FROM CEACAM1 FOR THE TREATMENT OF INFLAMMATORY DISEASES

1185 Avenue of the Americas
New York, New York 10036
June 16, 2006

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In order to ensure compliance with applicants' duty of disclosure under 37 C.F.R. §1.56 and §1.97(a)-(d), applicants request that the following documents be considered and made of record in the above-identified application which is listed on Form PTO-1449, attached hereto as **Exhibit A:**

1. International Search Report issued by the International Searching Authority (ISA/EP) on September 15, 2005 in connection with International Application No. PCT/EP2004/014435 **(Exhibit 1);**

2. Database Biosis Online! Biosciences Information Service, Philadelphia, PA, US; 2003. Hideki, I. et al. Specific Regulation Of T Helper-1 Mediated Murine Colitis By CEACAM1. XP002343170, Database Accession No. PREV200400032288 **(Exhibit 2);**

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

3. Szekanecz, Z. et al. Increased Synovial Expression Of The Adhesion Molecules CD66a, CD66b, and CD31 in Rheumatoid and Osteoarthritis. Clinical Immunology and Immunopathology, Vol. 76, No. 2, 1995, pages 180-186, XP002343166 **(Exhibit 3)**;

4. PCT International Application No. PCT/US99/08430 (Blumberg, R.), International Publication No. WO 99/52552, published on October 21, 1999 **(Exhibit 4)**;

5. Skubitz, K.M. et al. Synthetic Peptides From The N-Domains Of CEACAMs Activate Neutrophils. Journal of Peptide Research, Munksgaard International Publishers, Copenhagen, Denmark, Vol. 58, No. 6, December 2001, pages 515-526, XP001093434 **(Exhibit 5)**;

6. Hideki, I. et al. Specific Regulation Of T Helper Cell 1-Mediated Murine Colitis By CEACAM1. Journal Of Experimental Medicine. Vol. 199, No. 4, pages 471-482, XP002343167 **(Exhibit 6)**;

7. Chen D. et al. Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 1 Isoforms Alternatively Inhibit And Costimulate Human T Cell Function. Journal Of Immunology, Vol. 172, No. 6, pages 3535-3543, XP002343168 **(Exhibit 7)**;

8. Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/EP) on September 15, 2005 in connection with International Application No. PCT/EP2004/014435 **(Exhibit 8)**.

/Sharon Wen/ 01/26/2010

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

Copies of documents numbers 1-8 are attached hereto as **Exhibits 1-8**, respectively.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

10/583291

PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	NOT YET KNOWN
Filing Date	Herewith
First Named Inventor	Nalan Utku
Art Unit	
Examiner Name	
Attorney Docket Number	76518/JPW/CH

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T[6]
	4	WO 99/52552	10-21-1999	BLUMBERG, R.		

Examiner Signature	/Sharon Wen/	Date Considered	01/26/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1]Applicant's unique citation designation number (optional). [2]See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3]Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4]For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5]Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [6]Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.W./

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	NOT YET KNOWN
Filing Date	Herewith
First Named Inventor	Nalan Utku
Art Unit	
Examiner Name	
Attorney Docket Number	76518/JPW/CH

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	1	International Search Report issued by the International Searching Authority (ISA/EP) on September 15, 2005 in connection with International Application No. PCT/EP2004/014435	
	2	Database Biosis Online! Biosciences Information Service, Philadelphia, PA, US; 2003. HIDEKI, I. et al. Specific Regulation Of T Helper-1 Mediated Murine Colitis By CEACAM1. XP002343170, Database Accession No. PREV200400032288	
	3	SZEKANECZ, Z. et al. Increased Synovial Expression Of The Adhesion Molecules CD66a, CD66b, and CD31 in Rheumatoid and Osteoarthritis. Clinical immunology and immunopathology, Vol. 76, No. 2, 1995, pages 180-186, XP002343166	
	5	SKUBITZ, K.M. et al. Synthetic Peptides From The N-Domains Of CEACAMs Activate Neutrophils. Journal of Peptide Research, Munksgaard International Publishers, Copenhagen, Denmark, Vol. 58, No. 6, December 2001, pages 515-526, XP001093434	
	6	HIDEKI, I. et al. Specific Regulation Of T Helper Cell 1-Mediated Murine Colitis By CEACAM1. Journal Of Experimental Medicine. Vol. 199, No. 4, pages 471-482, XP002343167	
	7	CHEN D. et al. Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 1 Isoforms Alternatively Inhibit And Costimulate Human T Cell Function. Journal Of Immunology, Vol. 172, No. 6, pages 3535-3543, XP002343168	
	8	Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/EP) on September 15, 2005 in connection with International Application No. PCT/EP2004/014435	

Examiner Signature	/Sharon Wen/	Date Considered	01/26/2010

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.